SG Americas Securities LLC Lowers Holdings in Bioventus Inc. (NYSE:BVS)

SG Americas Securities LLC trimmed its position in Bioventus Inc. (NYSE:BVS) by 29.6% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 17,822 shares of the company’s stock after selling 7,493 shares during the period. SG Americas Securities LLC’s holdings in Bioventus were worth $213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mackenzie Financial Corp purchased a new position in Bioventus in the 2nd quarter valued at $77,000. The Manufacturers Life Insurance Company acquired a new stake in Bioventus in the second quarter valued at $87,000. Squarepoint Ops LLC lifted its holdings in Bioventus by 13.8% in the second quarter. Squarepoint Ops LLC now owns 26,171 shares of the company’s stock valued at $150,000 after acquiring an additional 3,170 shares during the period. Marshall Wace LLP lifted its holdings in Bioventus by 38.2% in the second quarter. Marshall Wace LLP now owns 332,291 shares of the company’s stock valued at $1,911,000 after acquiring an additional 91,843 shares during the period. Finally, Bank of Montreal Can acquired a new stake in Bioventus in the second quarter valued at $774,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Bioventus

In other news, Director John A. Bartholdson purchased 25,500 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was acquired at an average price of $8.55 per share, with a total value of $218,025.00. Following the purchase, the director now directly owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director John A. Bartholdson bought 25,500 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was purchased at an average price of $8.55 per share, with a total value of $218,025.00. Following the purchase, the director now owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John A. Bartholdson bought 80,000 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $8.55 per share, with a total value of $684,000.00. Following the purchase, the director now directly owns 6,913,857 shares in the company, valued at $59,113,477.35. The trade was a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 32.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on BVS. Canaccord Genuity Group raised their target price on Bioventus from $8.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, August 13th. Craig Hallum raised their target price on Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, September 27th.

Bioventus Price Performance

Bioventus stock opened at $12.97 on Wednesday. The company has a market cap of $1.03 billion, a P/E ratio of -37.06 and a beta of 0.90. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. Bioventus Inc. has a one year low of $2.97 and a one year high of $13.07. The business has a fifty day moving average of $10.74 and a two-hundred day moving average of $7.66.

Bioventus (NYSE:BVS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.12. The business had revenue of $151.22 million during the quarter, compared to the consensus estimate of $137.70 million. Bioventus had a positive return on equity of 14.39% and a negative net margin of 7.82%. During the same quarter in the previous year, the company posted $0.14 EPS. As a group, analysts predict that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.